# Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

> **NCT07075120** · PHASE1 · RECRUITING · sponsor: **University of Hawaii** · enrollment: 15 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Ipilimumab and Nivolumab
- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT07075120
- **Lead sponsor:** University of Hawaii
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07075120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07075120, "Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07075120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*